Assessing the Predictive Capability of Circulating Tumor DNA (ctDNA) as a Screening Tool for Ovarian Cancer
Eligibility
You can join if...
Inclusion Criteria
-Women ages 18 and older.
-Willing to undergo germline mutation testing as would be recommended within
routine clinical care.
-Undergoing RRSO or removal of an adnexal (ovarian or fallopian tube mass) within
routine clinical care
Exclusion Criteria
-Prior invasive malignancy other than squamous or basal cell carcinomas of the
skin or in situ cervical cancer
-Prior systemic chemotherapy or pelvic radiation treatment
-Germ cell and sex-cord stromal cell carcinomas on final pathologic evaluation will
not have prospective tissue preparation for DNA isolation and will be excluded
from additional analysis.